Alvogen appoints three new top executives

Posted on 30.3.2010 in: People

- New senior Management Team will build the next generation generics company

New Jersey, March 30th, 2010 - Alvogen Inc. (“Alvogen”), the US-based generic pharmaceutical company, today announces that three new top executives have joined its Executive Board. The new executives have an outstanding track record in the generic industry after holding senior executive positions with large global generic companies. As a part of the Group´s Executive Team, they are dedicated to build the next-generation generic pharmaceuticals company.

The new executives are:

Elin Gabriel
joins Alvogen as Chief Operating Officer effective May 2010.  With more than 20 years experience in manufacturing and supply chain management she is responsible for the global operations of Alvogen. Her scope of work at Alvogen includes creating and executing contemporary manufacturing and supply chain strategies to complement strategic business plans. Prior to joining the Alvogen leadership team, she was the senior VP for Croatia Operations and Barr-Teva Operation Integrations at Teva Pharmaceuticals.  Previously, she served as the Executive Vice President of Global Supply Chain and West-European operations for Actavis Group. Gabriel holds an MBA from the College of William and Mary and a B.S. degree in Chemical Engineering from North Carolina State University

Kevin Bain
is the Chief Financial Officer at Alvogen. With more than 25 years of financial, operations and general management experience, Bain is responsible for all finance and information technology functions for the worldwide Alvogen business. Prior to joining Alvogen in August 2009, Bain spent almost four years with Actavis Group, where he was Vice President of Finance & Operations for Actavis U.S and for more than twenty years he worked with the Johnson & Johnson Family of Companies. Bain graduated from the Accounting program at Fanshawe College in London, Ontario, Canada. He also holds a Certified Management Accountant (CMA) from the Society of Management Accountants of Ontario.

Svafa Gronfeldt
is the Chief Organizational Development Officer of Alvogen.  She is responsible for structure, strategy and human resources needed for a fast growing organization.  Previously she has managed multiple integration projects in more than 20 countries and led the organizational development of Actavis Group as the deputy CEO for a number of years. She is a PhD in Industrial Relations from the London School of Economics and has acquired over 20 years experience from academic and business leadership positions.

The Group´s Executive Board now consists of five individuals, all of whom have significant experience in the generic industry. Robert Wessman is the Executive Chairman of Alvogen, along with Doug Drysdale CEO, Kevin Bain CFO, Elin Gabriel Chief Operating Officer and Svafa Gronfeldt Chief Organizational Development Officer.

“These are proven leaders in the generic industry who bring a very valuable experience to their respective roles within Alvogen. They all have a proven track record of strong leadership and these individuals will play a critical role in the success of our organization. We are building a world class management team that will create the second generation generics company, that will by 2015 be one of the leading global players”, said Robert Wessman, Executive Chairman of Alvogen.